CATX
$4.95
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is...
Recent News
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share. The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the […]
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?
Perspective Therapeutics recently completed a US$174.99 million follow-on equity offering, issuing 39,576,088 shares of common stock at US$3.79 and 6,598,046 pre-funded warrants at US$3.789, as it works to advance its cancer-focused targeted alpha therapies program. This capital raise follows encouraging interim Phase 1/2a data for lead candidate VMT-α-NET using the alpha-emitting isotope Lead-212, which has drawn increased attention from the oncology and investment communities. We will now...
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates
Perspective Therapeutics (CATX) drew fresh attention after updated interim data from its Phase 1/2a VMT-a-NET trial showed sustained anti-tumor activity, along with a business update on pipeline priorities and manufacturing expansion plans. See our latest analysis for Perspective Therapeutics. The recent VMT-a-NET update arrived after a sharp rise in the share price, with a 39.85% 7-day share price return and a 45.77% 90-day share price return. Meanwhile, the 1-year total shareholder return...
Perspective Therapeutics: Q3 Earnings Snapshot
SEATTLE (AP) — Perspective Therapeutics, Inc. CATX) on Monday reported a loss of $26 million in its third quarter. The Seattle-based company said it had a loss of 35 cents per share.
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?